Navigation Links
TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug
Date:9/3/2013

Menlo Park, CA and Clearwater, FL (PRWEB) September 03, 2013

TesoRx Pharma, LLC and CoreRx, Inc. today announced a manufacturing joint venture to produce TSX-002, a first-in-class oral testosterone drug targeting the $2.5Billion low testosterone market. TesoRx’s novel, proprietary formulation orally delivers therapeutic levels of unmodified testosterone in a safe and convenient manner. The company will be commencing its final Phase 3 Clinical Study in Q1 of 2014.

“This joint venture solidifies our ability to manufacture TSX-002 to the highest standards in an environment that can easily scale from our current level through Phase 3 and, ultimately, commercial release,” said Ramachandran “TR” Thirucote, Ph.D., CEO of TesoRx. “The CoreRx team has set itself apart with its service commitment and innovation, making them an obvious choice as TesoRx moves to the next phase of development.”

“This project represents a significant expansion in both the size and mission of CoreRx,” said Todd R. Daviau, President and CEO. “An oral therapy is long overdue in the treatment of male hormone deficiency and is the cornerstone of TesoRx’s current portfolio. We are happy to have been chosen as TesoRx’s development partner and are looking forward to this long-term manufacturing project with TesoRx.”

The acquisition of the Myerlake II site will add approximately 47,000 sq.ft. of additional manufacturing and office space. TesoRx plans to begin construction in the buildings across from CoreRx’s current 35,000 sq.ft. facility in the ICOT Center campus. It will house several additional suites dedicated to process development, clinical trial manufacturing and commercial manufacturing of hormone products.

Work on the expansion has already begun and should be completed by the middle of Q2 2014.

About TesoRx, Inc.
TesoRx is a privately held pharmaceutical company focused on the development of a first-in-class unmodified oral testosterone for androgen deficiency. The company is advancing its proprietary pro-liposomal formulation of testosterone (TSX-002), through Phase 2 clinical studies for low testosterone in adult males. TSX-002 has the potential to be the first unmodified testosterone for oral delivery to enter the international market. The US market for topical, transdermal and injectable testosterone formulations alone is currently estimated at US $2.5 Billion with prescriptions having grown 34% over the last 12 months.

About CoreRx, Inc.
CoreRx is a contract research organization providing customized pre-formulation services, formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients. The company is renowned for reliably expediting early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. CoreRx's unique corporate structure creates project teams that work intensively with each client, bringing an extension of its own organization into the CoreRx lab.

Keep on top of new developments at CoreRx and throughout the drug development industry by following http://www.twitter.com/CoreRx and for more detailed information about the company, visit http://www.corerxpharma.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11082067.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
2. New Thermoelectric Peltier Cooler Announced by Oven Industries
3. JULABO USA Inc. Announces Update on Product Finder Tool
4. ATCC Announces Creation of Biomaterial Contributor Network
5. Suria Plastic Surgery Announces an Open House at Their Plantation, Florida Office
6. New Embedded Temperature Controllers Announced by Oven Industries
7. SCD-iBIO Announces Second International Forum on Commercializing Global Green
8. Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO
9. Pipette.com Has Announced Their Universal Pipette Filter Tip Promotion to Benefit Labs Dealing With Budget Cuts
10. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
11. Velocity Pharmaceutical Development and Tigercat Pharma Inc. Announce Submission of IND Application for VPD-737
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):